NAO Application icon

NAO 2.2.0

2.8 MB / 5K+ Downloads / Rating 3.7 - 26 reviews


See previous versions

NAO, developed and published by Araneum Group srl Italy, has released its latest version, 2.2.0, on 2017-10-31. This app falls under the Medical category on the Google Play Store and has achieved over 5000 installs. It currently holds an overall rating of 3.7, based on 26 reviews.

NAO APK available on this page is compatible with all Android devices that meet the required specifications (Android 4.0+). It can also be installed on PC and Mac using an Android emulator such as Bluestacks, LDPlayer, and others.

Read More

App Screenshot

App Screenshot

App Details

Package name: it.araneum.nao

Updated: 7 years ago

Developer Name: Araneum Group srl Italy

Category: Medical

New features: Show more

Installation Instructions

This article outlines two straightforward methods for installing NAO on PC Windows and Mac.

Using BlueStacks

  1. Download the APK/XAPK file from this page.
  2. Install BlueStacks by visiting http://bluestacks.com.
  3. Open the APK/XAPK file by double-clicking it. This action will launch BlueStacks and begin the application's installation. If the APK file does not automatically open with BlueStacks, right-click on it and select 'Open with...', then navigate to BlueStacks. Alternatively, you can drag-and-drop the APK file onto the BlueStacks home screen.
  4. Wait a few seconds for the installation to complete. Once done, the installed app will appear on the BlueStacks home screen. Click its icon to start using the application.

Using LDPlayer

  1. Download and install LDPlayer from https://www.ldplayer.net.
  2. Drag the APK/XAPK file directly into LDPlayer.

If you have any questions, please don't hesitate to contact us.

App Rating

3.7
Total 26 reviews

Previous Versions

NAO 2.2.0
2017-10-31 / 2.8 MB / Android 4.0+

About this app

I nuovi anticoagulanti orali rappresentano una valida alternativa alla terapia con warfarin nella prevenzione di ictus ed embolia sistemica in pazienti adulti con fibrillazione atriale non valvolare con almeno uno dei fattori di rischio per ictus.

Attualmente i NAO approvati in Europa e negli Stati Uniti sono dabigatran, rivaroxaban ed apixaban.

Questa applicazione consente di identificare la prescrivibilità e la posologia di dabigatran, rivaroxaban e apixaban in pazienti adulti con fibrillazione atriale non valvolare.

New features

informazioni su tromboembolismo venoso